Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients

Y. Chao, W. K. Chan, M. J. Birkhofer, O. Y.P. Hu, S. S. Wang, Y. S. Huang, M. Liu, J. Whang-Peng, K. H. Chi, W. Y. Lui, S. D. Lee

研究成果: 雜誌貢獻文章

109 引文 (Scopus)

摘要

Hepatocellular carcinoma (HCC) is a common lethal disease in Asia and there is no effective chemotherapy. Identification of new effective drugs in the treatment of inoperable HCC is urgently need. This is a phase II clinical study to investigate the efficacy, toxicity and pharmacokinetics of paclitaxel in HCC patients. Twenty patients with measurable, unresectable HCC, normal serum bilirubin, normal bone marrow and renal functions were studied. Paclitaxel 175 mg m-2 was given intravenously over 3 h every 3 weeks. No complete or partial responses were observed. Five patients had stable disease. Major treatment toxicities (grade 3-4) were neutropenia (25%), thrombocytopenia (15%), infection (10%) and allergy (10%). Treatment-related deaths occurred in two patients. The median survival was 12 weeks (range 1-36). Paclitaxel is metabolized by the liver and the pharmacokinetics of paclitaxel in cancer patients with liver involvement or impairment may be important clinically. Pharmacokinetic study was completed in 13 HCC patients. The paclitaxel area under the curve was significantly increased (P < 0.02), clearance decreased (P < 0.02) and treatment-related deaths increased (P = 0.03) in patients with hepatic impairment. In conclusion, paclitaxel in this dose and schedule has no significant anti-cancer effect in HCC patients. Paclitaxel should be used with caution in cancer patients with liver impairment.
原文英語
頁(從 - 到)34-39
頁數6
期刊British Journal of Cancer
78
發行號1
出版狀態已發佈 - 六月 26 1998
對外發佈Yes

指紋

Paclitaxel
Hepatocellular Carcinoma
Pharmacokinetics
Therapeutics
Liver
Neoplasms
Neutropenia
Bilirubin
Thrombocytopenia
Area Under Curve
Appointments and Schedules
Hypersensitivity
Bone Marrow
Kidney
Drug Therapy
Survival
Infection
Serum
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

引用此文

Chao, Y., Chan, W. K., Birkhofer, M. J., Hu, O. Y. P., Wang, S. S., Huang, Y. S., ... Lee, S. D. (1998). Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. British Journal of Cancer, 78(1), 34-39.

Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. / Chao, Y.; Chan, W. K.; Birkhofer, M. J.; Hu, O. Y.P.; Wang, S. S.; Huang, Y. S.; Liu, M.; Whang-Peng, J.; Chi, K. H.; Lui, W. Y.; Lee, S. D.

於: British Journal of Cancer, 卷 78, 編號 1, 26.06.1998, p. 34-39.

研究成果: 雜誌貢獻文章

Chao, Y, Chan, WK, Birkhofer, MJ, Hu, OYP, Wang, SS, Huang, YS, Liu, M, Whang-Peng, J, Chi, KH, Lui, WY & Lee, SD 1998, 'Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients', British Journal of Cancer, 卷 78, 編號 1, 頁 34-39.
Chao Y, Chan WK, Birkhofer MJ, Hu OYP, Wang SS, Huang YS 等. Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. British Journal of Cancer. 1998 6月 26;78(1):34-39.
Chao, Y. ; Chan, W. K. ; Birkhofer, M. J. ; Hu, O. Y.P. ; Wang, S. S. ; Huang, Y. S. ; Liu, M. ; Whang-Peng, J. ; Chi, K. H. ; Lui, W. Y. ; Lee, S. D. / Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. 於: British Journal of Cancer. 1998 ; 卷 78, 編號 1. 頁 34-39.
@article{cbbad8b82fe043d2bbddda16f0a924b3,
title = "Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients",
abstract = "Hepatocellular carcinoma (HCC) is a common lethal disease in Asia and there is no effective chemotherapy. Identification of new effective drugs in the treatment of inoperable HCC is urgently need. This is a phase II clinical study to investigate the efficacy, toxicity and pharmacokinetics of paclitaxel in HCC patients. Twenty patients with measurable, unresectable HCC, normal serum bilirubin, normal bone marrow and renal functions were studied. Paclitaxel 175 mg m-2 was given intravenously over 3 h every 3 weeks. No complete or partial responses were observed. Five patients had stable disease. Major treatment toxicities (grade 3-4) were neutropenia (25{\%}), thrombocytopenia (15{\%}), infection (10{\%}) and allergy (10{\%}). Treatment-related deaths occurred in two patients. The median survival was 12 weeks (range 1-36). Paclitaxel is metabolized by the liver and the pharmacokinetics of paclitaxel in cancer patients with liver involvement or impairment may be important clinically. Pharmacokinetic study was completed in 13 HCC patients. The paclitaxel area under the curve was significantly increased (P < 0.02), clearance decreased (P < 0.02) and treatment-related deaths increased (P = 0.03) in patients with hepatic impairment. In conclusion, paclitaxel in this dose and schedule has no significant anti-cancer effect in HCC patients. Paclitaxel should be used with caution in cancer patients with liver impairment.",
keywords = "Hepatic function, Hepatocellular carcinoma, Paclitaxel, Pharmacokinetic",
author = "Y. Chao and Chan, {W. K.} and Birkhofer, {M. J.} and Hu, {O. Y.P.} and Wang, {S. S.} and Huang, {Y. S.} and M. Liu and J. Whang-Peng and Chi, {K. H.} and Lui, {W. Y.} and Lee, {S. D.}",
year = "1998",
month = "6",
day = "26",
language = "English",
volume = "78",
pages = "34--39",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients

AU - Chao, Y.

AU - Chan, W. K.

AU - Birkhofer, M. J.

AU - Hu, O. Y.P.

AU - Wang, S. S.

AU - Huang, Y. S.

AU - Liu, M.

AU - Whang-Peng, J.

AU - Chi, K. H.

AU - Lui, W. Y.

AU - Lee, S. D.

PY - 1998/6/26

Y1 - 1998/6/26

N2 - Hepatocellular carcinoma (HCC) is a common lethal disease in Asia and there is no effective chemotherapy. Identification of new effective drugs in the treatment of inoperable HCC is urgently need. This is a phase II clinical study to investigate the efficacy, toxicity and pharmacokinetics of paclitaxel in HCC patients. Twenty patients with measurable, unresectable HCC, normal serum bilirubin, normal bone marrow and renal functions were studied. Paclitaxel 175 mg m-2 was given intravenously over 3 h every 3 weeks. No complete or partial responses were observed. Five patients had stable disease. Major treatment toxicities (grade 3-4) were neutropenia (25%), thrombocytopenia (15%), infection (10%) and allergy (10%). Treatment-related deaths occurred in two patients. The median survival was 12 weeks (range 1-36). Paclitaxel is metabolized by the liver and the pharmacokinetics of paclitaxel in cancer patients with liver involvement or impairment may be important clinically. Pharmacokinetic study was completed in 13 HCC patients. The paclitaxel area under the curve was significantly increased (P < 0.02), clearance decreased (P < 0.02) and treatment-related deaths increased (P = 0.03) in patients with hepatic impairment. In conclusion, paclitaxel in this dose and schedule has no significant anti-cancer effect in HCC patients. Paclitaxel should be used with caution in cancer patients with liver impairment.

AB - Hepatocellular carcinoma (HCC) is a common lethal disease in Asia and there is no effective chemotherapy. Identification of new effective drugs in the treatment of inoperable HCC is urgently need. This is a phase II clinical study to investigate the efficacy, toxicity and pharmacokinetics of paclitaxel in HCC patients. Twenty patients with measurable, unresectable HCC, normal serum bilirubin, normal bone marrow and renal functions were studied. Paclitaxel 175 mg m-2 was given intravenously over 3 h every 3 weeks. No complete or partial responses were observed. Five patients had stable disease. Major treatment toxicities (grade 3-4) were neutropenia (25%), thrombocytopenia (15%), infection (10%) and allergy (10%). Treatment-related deaths occurred in two patients. The median survival was 12 weeks (range 1-36). Paclitaxel is metabolized by the liver and the pharmacokinetics of paclitaxel in cancer patients with liver involvement or impairment may be important clinically. Pharmacokinetic study was completed in 13 HCC patients. The paclitaxel area under the curve was significantly increased (P < 0.02), clearance decreased (P < 0.02) and treatment-related deaths increased (P = 0.03) in patients with hepatic impairment. In conclusion, paclitaxel in this dose and schedule has no significant anti-cancer effect in HCC patients. Paclitaxel should be used with caution in cancer patients with liver impairment.

KW - Hepatic function

KW - Hepatocellular carcinoma

KW - Paclitaxel

KW - Pharmacokinetic

UR - http://www.scopus.com/inward/record.url?scp=7144257852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7144257852&partnerID=8YFLogxK

M3 - Article

C2 - 9662247

AN - SCOPUS:7144257852

VL - 78

SP - 34

EP - 39

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 1

ER -